<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056155</url>
  </required_header>
  <id_info>
    <org_study_id>DEC262-P002</org_study_id>
    <nct_id>NCT05056155</nct_id>
  </id_info>
  <brief_title>Systane Complete Multi-symptom Relief</brief_title>
  <official_title>Systane Complete Multi-symptom Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate effective symptom relief with the use of Systane&#xD;
      Complete among subjects with dry eye disease (DED).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be expected to attend a screening/baseline visit and one additional visit at&#xD;
      Day 28 (± 2 days), with a telephone call visit conducted at Day 14 (± 2 days). Individual&#xD;
      duration of subject participation will be approximately 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline at Day 28 in IDEEL-SB Question &quot;Sore&quot;</measure>
    <time_frame>Baseline (Day 0), Day 28</time_frame>
    <description>The Impact of Dry Eye on Everyday Life - Symptoms Bother (IDEEL-SB) is a patient-reported outcome measures questionnaire designed to assess symptoms of dry eye disease. Subjects will respond to the question, &quot;OVER THE LAST TWO WEEKS, how much did the following symptom bother you: Sore Eyes?&quot; using a 0-4 Likert-type scale, where 0 = &quot;I did not have this symptom/Not applicable&quot; and 4 = Very Much. A negative change value will represent perceived improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline at Day 28 in IDEEL-SB Question &quot;Stinging&quot;</measure>
    <time_frame>Baseline (Day 0), Day 28</time_frame>
    <description>Subjects will respond to the question, &quot;OVER THE LAST TWO WEEKS, how much did the following symptom bother you: Stinging Eyes?&quot; using a 0-4 Likert-type scale, where 0 = &quot;I did not have this symptom/Not applicable&quot; and 4 = Very Much. A negative change value will represent perceived improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline at Day 28 in IDEEL-SB Question &quot;Burning&quot;</measure>
    <time_frame>Baseline (Day 0), Day 28</time_frame>
    <description>Subjects will respond to the question, &quot;OVER THE LAST TWO WEEKS, how much did the following symptom bother you: Burning Eyes?&quot; using a 0-4 Likert-type scale, where 0 = &quot;I did not have this symptom/Not applicable&quot; and 4 = Very Much. A negative change value will represent perceived improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline at Day 28 in IDEEL-SB Question &quot;Tired Eyes&quot;</measure>
    <time_frame>Baseline (Day 0), Day 28</time_frame>
    <description>Subjects will respond to the question, &quot;OVER THE LAST TWO WEEKS, how much did the following symptom bother you: Tired Eyes?&quot; using a 0-4 Likert-type scale, where 0 = &quot;I did not have this symptom/Not applicable&quot; and 4 = Very Much. A negative change value will represent perceived improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline at Day 28 in DEQ-5 Question &quot;Watery&quot;</measure>
    <time_frame>Baseline (Day 0), Day 28</time_frame>
    <description>The Dry Eye Questionnaire-5 (DEQ-5) is a patient-reported outcome measures questionnaire designed to assess symptoms of dry eye disease. Subjects will respond to the question, &quot;During a typical day in the past month, how often did your eyes look or feel excessively watery?&quot; using a 0-4 Likert-type scale, where 0 = Never and 4 = Constantly. A negative change value will represent perceived improvement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Systane Complete</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of Systane Complete in both eyes on Day 0, followed by Systane Complete self-administered 4 times daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane Complete</intervention_name>
    <description>Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film</description>
    <arm_group_label>Systane Complete</arm_group_label>
    <other_name>Systane® Complete Lubricant Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and sign an Institutional Review Board (IRB)/Independent Ethics&#xD;
             Committee (IEC) approved informed consent form.&#xD;
&#xD;
          -  Willing and able to attend all study visits as required per protocol.&#xD;
&#xD;
          -  Have dry eye symptoms as specified in the protocol.&#xD;
&#xD;
          -  Willing to discontinue use of all habitual artificial tear supplements for the entire&#xD;
             study duration.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Ocular conditions as specified in the protocol.&#xD;
&#xD;
          -  Contact lens use within one week prior to screening visit.&#xD;
&#xD;
          -  Use of medications as specified in the protocol.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Ocular Health</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eye drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

